Phio Pharmaceuticals (NASDAQ:PHIO) Releases Earnings Results, Hits Estimates

Phio Pharmaceuticals (NASDAQ:PHIO) issued its quarterly earnings data on Thursday. The company reported ($0.36) EPS for the quarter, hitting analysts’ consensus estimates of ($0.36), FiscalAI reports.

Phio Pharmaceuticals Trading Up 0.2%

Shares of NASDAQ PHIO traded up $0.00 during midday trading on Friday, reaching $0.80. The company had a trading volume of 75,619 shares, compared to its average volume of 1,327,135. Phio Pharmaceuticals has a 1 year low of $0.75 and a 1 year high of $1.88. The business’s 50-day simple moving average is $0.98 and its 200 day simple moving average is $1.08. The stock has a market cap of $9.31 million, a P/E ratio of -0.62 and a beta of 0.93.

Wall Street Analysts Forecast Growth

PHIO has been the topic of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating on shares of Phio Pharmaceuticals in a research report on Wednesday, August 26th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Phio Pharmaceuticals in a research note on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $14.00.

Phio Pharmaceuticals Company Profile

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a biotechnology company focused on developing cancer immunotherapies. The company’s programs are designed to enhance the immune system’s ability to recognize and destroy tumor cells, with an emphasis on treatments that may be administered directly to the tumor or used in combination with other therapies.

Phio’s research is based on its INTASYL self-delivering RNA interference (RNAi) technology. The platform is intended to selectively silence genes involved in immune suppression and cancer progression without requiring a separate delivery vehicle.